Parexel International is enhancing its early-phase cardiac safety capabilities through a new alliance with Mortara Instrument, a worldwide manufacturer and distributor of ECG devices and related technology based in Milwaukee, WI. Specifically, Parexel will supplement its ECG equipment with Mortara Instrument's Surveyor Telemetry Central System, which is already in use at the company's Baltimore, MD, early phase clinical unit.
"This relationship represents our commitment to providing comprehensive early phase cardiovascular expertise and capabilities, such as intensive ECG and thorough QT/QTc studies, supported by enabling technologies,” said Michelle Middle, Parexel's corporate VP and worldwide head of early phase, in a company press release.
Mortara's high-tech solution will automate the process of acquiring and recording ECGs for Parexel, which are wirelessly transmitted from devices worn by clinical trial participants.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.